Español
India
Italiano
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Cellebrite DI
(NASDAQ:CLBT)
Intraday
$10.57
0.02
[0.19%]
After-Hours
$10.57
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$10.57
0.02
[0.19%]
At close: Jun 7
$10.57
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Cellebrite DI Stock (NASDAQ:CLBT)
Cellebrite DI Stock (NASDAQ: CLBT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, May 24, 2024
JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $14
Benzinga Newsdesk
Needham Maintains Buy on Cellebrite DI, Raises Price Target to $14
Benzinga Newsdesk
Thursday, May 23, 2024
Why Software Company Cellebrite Shares Are Up Today
Lekha Gupta
Cellebrite Continues To Expect FY24 Revenue Of $370M-$380M, Est $376.126M
Benzinga Newsdesk
Cellebrite Expects To Drive Solid ARR And Revenue Expansion In Q2; Sees Revenue Of $90M-$94M, Est $89.405M
Benzinga Newsdesk
Cellebrite DI Q1 2024 Adj EPS $0.08 Beats $0.06 Estimate, Sales $89.582M Beat $87.757M Estimate
Benzinga Newsdesk
Friday, April 19, 2024
Lake Street Initiates Coverage On Cellebrite DI with Buy Rating, Announces Price Target of $13
Benzinga Newsdesk
Monday, April 01, 2024
Craig-Hallum Maintains Buy on Cellebrite DI, Raises Price Target to $16
Benzinga Newsdesk
B of A Securities Maintains Buy on Cellebrite DI, Raises Price Target to $13
Benzinga Newsdesk
Thursday, March 28, 2024
Needham Maintains Buy on Cellebrite DI, Raises Price Target to $13.5
Benzinga Newsdesk
Wednesday, March 13, 2024
William Blair Upgrades Cellebrite DI to Outperform
Benzinga Newsdesk
Thursday, March 07, 2024
Cellebrite Launches FedRAMP Authorization Process To Provide Federal Customers With Enhanced Cloud Security
Benzinga Newsdesk
Friday, February 16, 2024
Cellebrite DI shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and announced a $12 price target.
Benzinga Newsdesk
B of A Securities Upgrades Cellebrite DI to Buy, Announces $12 Price Target
Benzinga Newsdesk
Thursday, February 15, 2024
Needham Maintains Buy on Cellebrite DI, Raises Price Target to $13
Benzinga Newsdesk
Cellebrite DI Q4 2023 Adj EPS $0.11 Beats $0.06 Estimate, Sales $93.01M Beat $85.54M Estimate
Benzinga Newsdesk
Earnings Scheduled For February 15, 2024
Benzinga Insights
Wednesday, December 20, 2023
Cellebrite DI Ltd. Announces One Of The Largest Police Departments In The U.S. Doubles Down With Cellebrite Digital Forensic Technology
Benzinga Newsdesk
Tuesday, November 14, 2023
Earnings Scheduled For November 14, 2023
Benzinga Insights
Cellebrite DI: Q3 Earnings Insights
Benzinga Insights
Cellebrite DI Ltd Expects FY23 Revenue of $315M-$320M (Prior $310M-$320M) Vs $316.15M Est
Benzinga Newsdesk
Cellebrite DI Q3 Adj EPS $0.09 Beats $0.05 Estimate, Sales $84.18M Beat $82.13M Estimate
Benzinga Newsdesk
Tuesday, September 19, 2023
Watching Cellebrite DI; Hearing Popular Microcap Newsletter Picks Stock
Benzinga Newsdesk
Wednesday, August 30, 2023
What 4 Analyst Ratings Have To Say About Cellebrite DI
Benzinga Insights
Needham Reiterates Buy on Cellebrite DI, Maintains $10 Price Target
Benzinga Newsdesk
Wednesday, August 09, 2023
Expert Ratings for Cellebrite DI
Benzinga Insights
JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $10
Benzinga Newsdesk
Needham Maintains Buy on Cellebrite DI, Raises Price Target to $10
Benzinga Newsdesk
Tuesday, August 08, 2023
Cellebrite DI shares are trading higher after the company reported better-than-expected Q2 financial results and raised FY23 revenue guidance.
Benzinga Newsdesk
Cellebrite Appoints Thomas E. Hogan as Executive Chairman of the Board. Current Non-Executive Chairman, Haim Shani Will Remain an Active Member of the Board
Benzinga Newsdesk
Cellebrite DI Raises FY2023 Sales Guidance from $305.00M-315.00M to $310.00M-320.00M vs. $310.75M Estimate
Benzinga Newsdesk
Cellebrite DI Q2 Adj. EPS $0.05 Beats $0.03 Estimate, Sales $76.68M Beat $72.46M Estimate
Benzinga Newsdesk
Earnings Scheduled For August 8, 2023
Benzinga Insights
Monday, August 07, 2023
Preview: Cellebrite DI's Earnings
Benzinga Insights
Wednesday, July 19, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2023
Benzinga Insights
Craig-Hallum Initiates Coverage On Cellebrite DI with Buy Rating, Announces Price Target of $11
Benzinga Newsdesk
Monday, May 22, 2023
Cellebrite Bolsters Digital Intelligence Capabilities For Latin American Nation's Federal Forces And Expands Investigative Power Around Crypto Crime
Benzinga Newsdesk
Wednesday, May 17, 2023
Needham Reiterates Buy on Cellebrite DI, Maintains $7 Price Target
Benzinga Newsdesk
Thursday, May 11, 2023
Needham Reiterates Buy on Cellebrite DI, Maintains $7 Price Target
Benzinga Newsdesk
Wednesday, May 10, 2023
Earnings Scheduled For May 10, 2023
Benzinga Insights
Recap: Cellebrite DI Q1 Earnings
Benzinga Insights
Cellebrite Sees FY23 Revenue Of 4305M - $315M Vs. $309.48M Est.
Benzinga Newsdesk
Cellebrite DI Q1 Adj EPS $0.03 Beats $0.02 Estimate, Sales $71.20M Beat $69.44M Estimate
Benzinga Newsdesk
Tuesday, March 14, 2023
Overview Of Value Stocks In The Technology Sector
Benzinga Insights
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
Lisa Levin
Needham Maintains Buy on Cellebrite DI, Raises Price Target to $7
Benzinga Newsdesk
Thursday, February 16, 2023
Needham Reiterates Buy on Cellebrite DI, Maintains $6.5 Price Target
Benzinga Newsdesk
Wednesday, February 15, 2023
Cellebrite shares are trading higher after the company reported better-than-expected Q4 EPS.
Bill Haddad
Cellebrite Sees FY23 Revenue Of $305M-$315M
Benzinga Newsdesk
Cellebrite DI Q4 Adj EPS $0.08 Beats $0.04 Estimate, Sales $74.00M Miss $74.73M Estimate
Benzinga Newsdesk
Show more